Sunmax Biotechnology Statistics

Total Valuation

Sunmax Biotechnology has a market cap or net worth of TWD 14.92 billion. The enterprise value is 14.42 billion.

Market Cap	14.92B
Enterprise Value	14.42B

Important Dates

The next estimated earnings date is Thursday, March 27, 2025.

Earnings Date	Mar 27, 2025
Ex-Dividend Date	Jul 17, 2024

Share Statistics

Sunmax Biotechnology has 54.46 million shares outstanding. The number of shares has decreased by -0.06% in one year.

Current Share Class	n/a
Shares Outstanding	54.46M
Shares Change (YoY)	-0.06%
Shares Change (QoQ)	+0.06%
Owned by Insiders (%)	11.75%
Owned by Institutions (%)	6.95%
Float	33.29M

Valuation Ratios

The trailing PE ratio is 21.37.

PE Ratio	21.37
Forward PE	n/a
PS Ratio	8.56
PB Ratio	10.92
P/TBV Ratio	10.94
P/FCF Ratio	31.33
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.31, with an EV/FCF ratio of 30.28.

EV / Earnings	20.64
EV / Sales	8.27
EV / EBITDA	14.31
EV / EBIT	15.79
EV / FCF	30.28

Financial Position

The company has a current ratio of 3.40, with a Debt / Equity ratio of 0.11.

Current Ratio	3.40
Quick Ratio	2.66
Debt / Equity	0.11
Debt / EBITDA	0.15
Debt / FCF	0.32
Interest Coverage	149.96

Financial Efficiency

Return on equity (ROE) is 53.12% and return on invested capital (ROIC) is 38.71%.

Return on Equity (ROE)	53.12%
Return on Assets (ROA)	29.90%
Return on Capital (ROIC)	38.71%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.91
Inventory Turnover	2.79

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +36.97% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+36.97%
50-Day Moving Average	274.46
200-Day Moving Average	269.90
Relative Strength Index (RSI)	43.92
Average Volume (20 Days)	61,059

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sunmax Biotechnology had revenue of TWD 1.74 billion and earned 698.95 million in profits. Earnings per share was 12.82.

Revenue	1.74B
Gross Profit	1.43B
Operating Income	913.53M
Pretax Income	945.34M
Net Income	698.95M
EBITDA	976.96M
EBIT	913.53M
Earnings Per Share (EPS)	12.82

Full Income Statement

Balance Sheet

The company has 653.50 million in cash and 154.77 million in debt, giving a net cash position of 498.73 million or 9.16 per share.

Cash & Cash Equivalents	653.50M
Total Debt	154.77M
Net Cash	498.73M
Net Cash Per Share	9.16
Equity (Book Value)	1.37B
Book Value Per Share	25.10
Working Capital	600.84M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 550.17 million and capital expenditures -73.80 million, giving a free cash flow of 476.37 million.

Operating Cash Flow	550.17M
Capital Expenditures	-73.80M
Free Cash Flow	476.37M
FCF Per Share	8.75

Full Cash Flow Statement

Margins

Gross margin is 81.97%, with operating and profit margins of 52.40% and 40.09%.

Gross Margin	81.97%
Operating Margin	52.40%
Pretax Margin	54.23%
Profit Margin	40.09%
EBITDA Margin	56.04%
EBIT Margin	52.40%
FCF Margin	27.32%

Dividends & Yields

This stock pays an annual dividend of 11.00, which amounts to a dividend yield of 4.01%.

Dividend Per Share	11.00
Dividend Yield	4.01%
Dividend Growth (YoY)	15.79%
Years of Dividend Growth	5
Payout Ratio	85.71%
Buyback Yield	0.06%
Shareholder Yield	4.08%
Earnings Yield	4.68%
FCF Yield	3.19%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sunmax Biotechnology has an Altman Z-Score of 19.26.

Altman Z-Score	19.26
Piotroski F-Score	n/a